Development of BIO 300 oral tabs

Other Transaction IDV Awarded Last action

Contract number
W911SR2390018
Awardee
Awarding agency
Task orders
0

Award facts

Last date to order
Not on record
IDV ceiling
$24,374,208.00
Funding agency
Joint PEO Chemical and Biological Defense Acquisition Support Center, Department of Defense
NAICS code
Not on record
Set-aside
No set-aside
Competition
Competed Broad Agency Announcement
Pricing
Other

Award details come from SAM.gov/FPDS.

About this IDV

The Department of Defense Joint PEO Chemical and Biological Defense awarded an Other Transaction IDV to Humanetics Corporation on August 10, 2023, with a ceiling of $24.37 million to support advanced development of BIO 300 oral tablets as a prophylactic medical countermeasure for acute radiation syndrome. This OT IDV operates outside the FAR procurement framework and supports the transition of an existing therapeutic candidate from preclinical development into clinical and regulatory pathways.

Humanetics Corporation is a biopharmaceutical company focused on medical countermeasures for radiation exposure. The company brings established capability in formulation development and regulatory strategy for radiation mitigation treatments, including prior work on BIO 300 and BIO 301 candidates funded through grants from the National Institutes of Health, the Department of Defense, and the Department of the Army.

The OT IDV aims to develop an oral formulation of BIO 300 as an alternative delivery mechanism to the existing therapeutic. Work encompasses the necessary preclinical and clinical studies required to achieve regulatory approval. Performance occurs at Humanetics facilities and partner sites. Task orders issued under this IDV will fund discrete development projects across the vehicle's performance period.

Transactions

Action Obligated Date
Supplemental Agreement for work within scope P00008 $0
Funding Only Action P00007 $0
Other Administrative Action P00006 $0
Supplemental Agreement for work within scope P00005 · The purpose of this agreement is advanced development of "BIO 300" oral tablets as a prophylactic medical countermeasure for acute radiation syndrome. $4,874,770
Other Administrative Action P00004 $0
Other Administrative Action P00003 $0
Other Administrative Action P00002 $0
Other Administrative Action P00001 $0
Original award $19,499,438

Quick answers

Who was awarded contract W911SR2390018?

W911SR2390018 was awarded to Humanetics Corporation by ACC Aberdeen Proving Ground (Army Contracting Command) on August 10, 2023.

How much is contract W911SR2390018 worth?

W911SR2390018's own ceiling is $24,374,208.

Which agency awarded contract W911SR2390018?

ACC Aberdeen Proving Ground (Army Contracting Command) awarded W911SR2390018, with funding from Joint PEO Chemical and Biological Defense (Acquisition Support Center).

Was contract W911SR2390018 competed?

The extent of competition for W911SR2390018 was competed.

On GovTribe

See this IDV's full record

  • Every order and transaction
  • The awardee's other awards and teaming partners
  • Similar IDVs and recompete opportunities
  • Ask GovTribe AI about this IDV